Literature DB >> 2694347

Adverse reactions to furazolidone and other drugs. A comparative review.

A Altamirano1, A Bondani.   

Abstract

Furazolidone is a synthetic nitrofuran with a broad spectrum of antimicrobial action and has been widely used in the treatment of gastrointestinal infections. This article reviews the adverse reactions to furazolidone reported in the world literature. Of 10,443 adults and children who were treated with the drug, approximately 8.3% (864) experienced such reactions. Because some of these patients had more than 1 adverse reaction, 1178 reactions were reported in these studies. Nausea with vomiting, the commonest adverse reaction, was reported by 51% of the 864 patients who experienced adverse reactions. The authors compare the adverse reactions to furazolidone with those reported for other antimicrobial and antiprotozoal drugs that are frequently used to treat gastrointestinal infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694347     DOI: 10.3109/00365528909091336

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  13 in total

1.  Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone.

Authors:  D Dionisio; L I Manneschi; S Di Lollo; A Orsi; G Sterrantino; M Meli; M Gabbrielli; A Tani; A Papucci; F Leoncini
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 2.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

3.  Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers.

Authors:  S A Calafatti; R A Ortiz; M Deguer; M Martinez; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

Review 4.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran.

Authors:  Marjan Mohammadi; Bahareh Attaran; Reza Malekzadeh; David Y Graham
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

6.  Persistent damage to Enterocytozoon bieneusi, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients.

Authors:  D Dionisio; L I Manneschi; S Di Lollo; A Orsi; G Sterrantino; F Leoncini; M Pozzi; M A Vinattieri; A Tani; A Papucci
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

7.  Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

Authors:  Hong Cheng; Fu-Lian Hu
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

8.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

9.  Helicobacter pylori eradication therapy: A review of current trends.

Authors:  A B Olokoba; O A Obateru; M O Bojuwoye
Journal:  Niger Med J       Date:  2013-01

10.  Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication.

Authors:  Ya-Wen Zhang; Wei-Ling Hu; Yuan Cai; Wen-Fang Zheng; Qin Du; John J Kim; John Y Kao; Ning Dai; Jian-Min Si
Journal:  World J Gastroenterol       Date:  2018-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.